BioNTech Surges On This Promising Update In Its Bid To Take On Bristol Myers In Lung Cancer TreatmentInvestors Business Daily • Friday
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCOGlobeNewsWire • Friday
2 Undervalued Stocks to Buy for Potentially Massive Gains in the Next 10 YearsThe Motley Fool • 05/23/23
BioNTech Stock Jumps As Covid Vaccine Sales, Profits Beat ExpectationsInvestors Business Daily • 05/08/23
BioNTech reports strong 1Q earnings; expands focus beyond Covid-19 vaccinesProactive Investors • 05/08/23
FDA authorizes Pfizer-BioNTech booster for young kids with compromised immune systemsMarket Watch • 04/28/23
BioNTech to Report First Quarter 2023 Financial Results and Operational Update on May 8, 2023GlobeNewsWire • 04/24/23